Ensilicated Technologies
Silica-based biomolecule stabilization technology for biopharmaceutical developers seeking to reduce cold-chain dependence
Highlights
- New on EvolcAdded 2026-11-12
About Ensilicated Technologies
Ensilicated Technologies develops ensilication, a method that encases thermally unstable biomolecules in a silica network to protect them from degradation and improve shelf-life. The process is designed for existing and new biopharmaceutical formulations and does not rely on lyophilisation or harsh conditions.
Applications include vaccines, therapeutic and diagnostic antibodies, genetic material, enzymes, probiotics and laboratory research products. The company seeks partners to develop applications of the technology.
Ensilicated Technologies Ltd was founded in 2021 and is headquartered in Bristol, UK.
Product: A silica-based stabilization method for biomolecules, intended to protect biopharmaceutical products from environmental degradation and reduce cold-chain requirements.
Jobs at Ensilicated Technologies
Leadership
- Matt Slade · Co-Founder, Chief of StaffSource: company website
- Asel Sartbaeva · Co-Founder, Chief Executive OfficerSource: company website
- Aswin Doekhie · Co-Founder, Chief Technical OfficerSource: company website
- Sabine Ficek · Chief Financial OfficerSource: company website
More biotech & pharma companies
Ensocell
AI-driven discovery of precision therapies for fibrotic and autoimmune diseases using human biological dataYoung companyEnterobiotix
Clinical-stage microbiome therapeutics developer advancing oral EBX-102-02 for irritable bowel syndrome and seeking licensing partnersEnterprise Therapeutics
Develops investigational medicines for people with cystic fibrosis and other respiratory diseasesEntropix
Enzyme engineering and biomolecule purification technologies for life-science, diagnostics and industrial customersNew on EvolcEpidarex Exeed
Seeds early-stage life science ventures by developing breakthrough therapeutic research into investable assetsEpitopea
RNA-based cancer immunotherapies and antigen-discovery technology for cancer patients and research partners
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- SquarespaceHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.